1. Home
  2. GAM vs ALMR Comparison

GAM vs ALMR Comparison

Compare GAM & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo General American Investors Inc.

GAM

General American Investors Inc.

HOLD

Current Price

$62.86

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Alamar Biosciences Inc. Common Stock

ALMR

Alamar Biosciences Inc. Common Stock

N/A

Current Price

$26.52

Market Cap

1.5B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
GAM
ALMR
Founded
1927
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
GAM
ALMR
Price
$62.86
$26.52
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
29.6K
243.4K
Earning Date
01-01-0001
N/A
Dividend Yield
5.74%
N/A
EPS Growth
N/A
N/A
EPS
11.67
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$55.09
$21.58
52 Week High
$66.18
$24.58

Technical Indicators

Market Signals
Indicator
GAM
ALMR
Relative Strength Index (RSI) 44.60 N/A
Support Level $62.50 N/A
Resistance Level $62.83 N/A
Average True Range (ATR) 1.05 0.00
MACD -0.10 0.00
Stochastic Oscillator 27.04 0.00

Price Performance

Historical Comparison
GAM
ALMR

About GAM General American Investors Inc.

General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.

About ALMR Alamar Biosciences Inc. Common Stock

Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.

Share on Social Networks: